XML 37 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue recognition and accounts receivable (Tables)
9 Months Ended
Sep. 30, 2025
Revenue Recognition And Accounts Receivable [Abstract]  
Schedule of Net Sales by Product Category by Reporting Segment

The tables below present net sales by product category by reporting segment:

 

 

Three Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2025

 

 

2024

 

 

Change

 

Bone Growth Therapies

 

$

61,211

 

 

$

57,925

 

 

 

5.7

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

110,852

 

 

 

108,179

 

 

 

2.5

%

Global Spine

 

 

172,063

 

 

 

166,104

 

 

 

3.6

%

Global Orthopedics

 

 

33,571

 

 

 

30,502

 

 

 

10.1

%

Net sales

 

$

205,634

 

 

$

196,606

 

 

 

4.6

%

 

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2025

 

 

2024

 

 

Change

 

Bone Growth Therapies

 

$

178,834

 

 

$

169,537

 

 

 

5.5

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

326,889

 

 

 

325,894

 

 

 

0.3

%

Global Spine

 

 

505,723

 

 

 

495,431

 

 

 

2.1

%

Global Orthopedics

 

 

96,678

 

 

 

88,403

 

 

 

9.4

%

Net sales

 

$

602,401

 

 

$

583,834

 

 

 

3.2

%

Schedule of Components Net Sales

The table below presents product sales and marketing service fees, which are both components of net sales:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Product sales

 

$

193,813

 

 

$

184,040

 

 

$

566,841

 

 

$

545,288

 

Marketing service fees

 

 

11,821

 

 

 

12,566

 

 

 

35,560

 

 

 

38,546

 

Net sales

 

$

205,634

 

 

$

196,606

 

 

$

602,401

 

 

$

583,834

 

Allowances for Expected Credit Losses

The following table provides a detail of changes in the Company's allowance for expected credit losses for the three and nine months ended September 30, 2025 and 2024:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Allowance for expected credit losses beginning balance

 

$

8,909

 

 

$

8,368

 

 

$

7,418

 

 

$

7,130

 

Current period provision for expected credit losses

 

 

629

 

 

 

486

 

 

 

2,466

 

 

 

2,059

 

Write-offs charged against the allowance and other

 

 

(112

)

 

 

(1,118

)

 

 

(870

)

 

 

(1,321

)

Effect of changes in foreign exchange rates

 

 

(13

)

 

 

142

 

 

 

399

 

 

 

10

 

Allowance for expected credit losses ending balance

 

$

9,413

 

 

$

7,878

 

 

$

9,413

 

 

$

7,878